Alvotech 관리

관리 기준 확인 4/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Robert Wessman

최고 경영자

US$2.3m

총 보상

CEO 급여 비율	93.67%
CEO 임기	2.3yrs
CEO 소유권	n/a
경영진 평균 재임 기간	2yrs
이사회 평균 재임 기간	3.9yrs

최근 관리 업데이트

Recent updates

Bullish: Analysts Just Made A Huge Upgrade To Their Alvotech (NASDAQ:ALVO) Forecasts

May 28

Alvotech: Consider Buying As Positive Q1 Earnings Release Likely

Apr 25

Alvotech (NASDAQ:ALVO) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Apr 03

Alvotech (NASDAQ:ALVO) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 24

Analysts Just Shaved Their Alvotech (NASDAQ:ALVO) Forecasts Dramatically

Sep 03

Positive Sentiment Still Eludes Alvotech (NASDAQ:ALVO) Following 27% Share Price Slump

May 05

Shareholders Shouldn’t Be Too Comfortable With Alvotech's (NASDAQ:ALVO) Strong Earnings

Nov 23

CEO 보상 분석

Robert Wessman 의 보수는 Alvotech 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2025	n/a	n/a	US$97m
Dec 31 2024	US$2m	US$2m	-US$232m
Sep 30 2024	n/a	n/a	-US$441m
Jun 30 2024	n/a	n/a	-US$618m
Mar 31 2024	n/a	n/a	-US$494m
Dec 31 2023	US$2m	US$1m	-US$552m
Sep 30 2023	n/a	n/a	-US$596m
Jun 30 2023	n/a	n/a	-US$416m
Mar 31 2023	n/a	n/a	-US$713m
Dec 31 2022	US$740k	n/a	-US$514m

보상 대 시장: Robert 의 총 보상 ($USD 2.32M ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 7.59M ).

보상과 수익: Robert 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Robert Wessman (54 yo)

2.3yrs

테뉴어

US$2,323,000

보상

Mr. Robert Wessman serves as Chief Executive Officer of Alvotech since January 1, 2023. He Founded Alvotech in 2013 and serves as its Executive Chairman and Member of the Board of Directors since January 2...

리더십 팀

이름	위치	테뉴어	보상	소유권
Robert Wessman	CEO, Founder & Executive Chairman	2.3yrs	US$2.32m	데이터 없음
Faysal Kalmoua	COO & Director	1.7yrs	데이터 없음	0% $ 0
Joel Morales	Chief Financial Officer	5.3yrs	데이터 없음	0.032% $ 964.5k
Giedrius Zunda	Chief Technical Officer	no data	데이터 없음	데이터 없음
Joseph McClellan	Chief Scientific Officer	5.6yrs	데이터 없음	0.051% $ 1.5m
Benedikt Stefansson	VP of Investor Relations and Global Communications	no data	데이터 없음	데이터 없음
Tanya Zharov	General Counsel	2.3yrs	데이터 없음	0% $ 0
Jenny Steingrimsdottir	Vice President of People & Culture	1.1yrs	데이터 없음	데이터 없음
Anil Okay	Chief Commercial Officer	6.8yrs	데이터 없음	데이터 없음
Anthony Maffia	Chief Regulatory Affairs Officer	1.3yrs	데이터 없음	데이터 없음
Uri Hillel	Chief Quality Officer	less than a year	데이터 없음	데이터 없음
Balaji Prasad	Chief Strategy Officer	less than a year	데이터 없음	데이터 없음

2.0yrs

평균 재임 기간

49yo

평균 연령

경험이 풍부한 관리: ALVO 의 관리팀은 경험 ( 2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Robert Wessman	CEO, Founder & Executive Chairman	6.3yrs	US$2.32m	데이터 없음
Faysal Kalmoua	COO & Director	4.9yrs	데이터 없음	0% $ 0
Hjorleifur Palsson	Director	no data	US$41.00k	0.00078% $ 23.4k
Linda McGoldrick	Independent Non-Executive Director	2.9yrs	US$275.00k	0.0070% $ 210.3k
Lisa Graver	Non-Executive Director	2.9yrs	US$251.00k	0.0070% $ 210.3k
Tomas Ekman	Non-Executive Director	6.3yrs	데이터 없음	데이터 없음
Arni Hardarson	Non-Executive Director	2.9yrs	데이터 없음	데이터 없음
Richard Davies	Independent Non-Executive Deputy Chairman	6.3yrs	US$339.00k	0.36% $ 10.8m
Ann Merchant	Independent Non-Executive Director	2.9yrs	US$295.00k	0.0070% $ 210.3k

3.9yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 이사회: ALVO 의 이사회는 경험(평균 재직 기간 3.9 년)으로 간주됩니다.

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/05/23 03:41
장 마감 주가	2025/05/23 00:00
수익	2025/03/31
연간 수익	2024/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Alvotech 7 애널리스트 중 5 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Andrew Baum	Citigroup Inc
Peter Verdult	Citigroup Inc
Emmanuel Papadakis	Deutsche Bank

Alvotech 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Alvotech Appoints Balaji V. Prasad as Chief Strategy Officer

Alvotech Appoints Hjörleifur Pálsson as Director

Alvotech, Annual General Meeting, Jun 07, 2024

Alvotech Announces Executive Changes

Alvotech Announces Changes to the Leadership Team

Alvotech, Annual General Meeting, Jun 06, 2023

Recent updates

Alvotech has completed a Follow-on Equity Offering in the amount of SEK 38.644416 million.

Alvotech's (NASDAQ:ALVO) Promising Earnings May Rest On Soft Foundations

Alvotech Provides Revenue Guidance for the Year 2025

Teva Pharmaceuticals and Alvotech Announce FDA Approval of Interchangeability for SELARSDI (Ustekinumab-Aekn) with Stelara®? (Ustekinumab)

Biosimilar Pipeline And R&D Capability Will Open New Markets

Alvotech: Potential Victim Of Pharma Tariff Threats (Rating Downgrade)

Benign Growth For Alvotech (NASDAQ:ALVO) Underpins Stock's 25% Plummet

Alvotech Appoints Balaji V. Prasad as Chief Strategy Officer

Alvotech , Kashiv Biosciences LLC and Advanz Pharma Announces UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)

Alvotech to Report Fiscal Year 2024 Results on Mar 26, 2025

Teva Pharmaceuticals and Alvotech Announces the Availability of Selarsdi™? (Ustekinumab-Aekn) Injection in the U.S

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea®? (Aflibercept)

Alvotech and Teva Pharmaceuticals Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, A Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

Alvotech to Report Q2, 2025 Results on Aug 14, 2025

Alvotech's Position In The Coming Biosimilar Gold Rush

European Medicines Agency Confirms Acceptance of Marketing Authorization Application for Avt05, A Proposed Biosimilar to Simponi (Golimumab)

Alvotech and Teva Pharmaceutical Industries Ltd. Announce U.S. FDA Approval of Additional Presentation of SELARSDI (ustekinumab-aekn)

Alvotech Announces European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, Proposed Biosimilar to Prolia and Xgeva

Alvotech Initiates Confirmatory Patient Study for AVT16

Alvotech: Steady Progress Offers A Good Chance Of Upside

Alvotech announces the European Medicines Agency Accepts a Marketing Authorization Application for AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)

STADA and Alvotech Launch Uzpruvo

Alvotech Announces Positive Topline Results from Confirmatory Patient Study for Avt03, A Proposed Biosimilar for Prolia® and Xgeva®

Alvotech has filed a Follow-on Equity Offering in the amount of $75 million.

Alvotech Appoints Hjörleifur Pálsson as Director

Bullish: Analysts Just Made A Huge Upgrade To Their Alvotech (NASDAQ:ALVO) Forecasts

Consensus revenue estimates increase by 15%

First quarter 2024 earnings released: US$0.89 loss per share (vs US$1.24 loss in 1Q 2023)

Alvotech, Annual General Meeting, Jun 07, 2024

Alvotech: Consider Buying As Positive Q1 Earnings Release Likely

Alvotech Announces Topline Results from A Confirmatory Clinical Study for AVT05, A Proposed Biosimilar for Simponi (Golimumab)

Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)

Alvotech (NASDAQ:ALVO) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Consensus EPS estimates fall by 28%, revenue upgraded

Price target increased by 10% to US$16.17

Alvotech (NASDAQ:ALVO) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

Alvotech Announces Executive Changes

Price target increased by 9.6% to US$12.33

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva

Alvotech Provides Update on Status of Biologics License Applications for Avt02 and Avt04

STADA and Alvotech Secure Approval for Uzpruvo, Europe’s First Ustekinumab Biosimilar to Stelara

Consensus revenue estimates increase by 45%

Consensus revenue estimates decrease by 41%, EPS upgraded

New major risk - Financial position

Third quarter 2023 earnings released: US$0.81 loss per share (vs US$0.04 loss in 3Q 2022)

Alvotech Announces Positive Top-Line Results from A Pharmacokinetic Study for Avt05

Light Curve Capital Holdings Pte. Ltd made an offer to acquire Alvotech Hannover Gmbh from Alvotech (NasdaqGM:ALVO).

STADA and Alvotech Receive Positive CHMP Opinion for Europe's First Ustekinumab Biosimilar to Stelara

Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04

Price target decreased by 25% to US$8.10

Alvotech Announces Approval in Japan of Avt04 (Ustekinumab), A Biosimilar to Stelara®

Alvotech Announces U.S. Food and Drug Administration Accepts its Resubmitted Biologics License Application (BLA) for AVT02

Alvotech Announces Changes to the Leadership Team

Consensus revenue estimates fall by 26%

Analysts Just Shaved Their Alvotech (NASDAQ:ALVO) Forecasts Dramatically

Forecast breakeven date pushed back to 2025

Second quarter 2023 earnings released: EPS: US$0.85 (vs US$0.58 loss in 2Q 2022)

Alvotech and Bioventure Announces Approval of AVT02 (Adalimumab) in Egypt

Alvotech announced that it expects to receive $40 million in funding from Teva Pharmaceutical Industries Limited

Alvotech to Report Q3, 2023 Results on Nov 14, 2023

Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02

New minor risk - Share price stability

Consensus revenue estimates decrease by 15%, EPS upgraded

Forecast breakeven date moved forward to 2024

Price target decreased by 8.8% to US$12.40

First quarter 2023 earnings released: US$1.24 loss per share (vs US$0.51 loss in 1Q 2022)

Alvotech, Annual General Meeting, Jun 06, 2023